Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials
Ismaila Ajayi Yusuf, Olurotimi J. Badero, Alozie Ihesiulo, Micah Nnabuko Okwah, Abieyuwa Oshodin, Emmanuella Asikong, James Wright, James Wright, James Wright · 2026
Read Aldosterone synthase inhibitors in uncontrolled and resistant hypertension: A phenotype-stratified systematic review and network meta-analysis of randomized trials by Ismaila Ajayi Yusuf, Olurotimi J. Badero, Alozie Ihesiulo, Micah Nnabuko Okwah, Abieyuwa Oshodin, Emmanuella Asikong, James Wright, James Wright, James Wright (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13232938.txt.
Description
Ismaila Ajayi Yusuf and colleagues issued a 2026 review comparing a new class of blood pressure drugs called aldosterone synthase inhibitors. These drugs block the making of aldosterone, a hormone that raises blood pressure. No trial has tested the drugs against each other directly, so the team combined seven randomized trials covering 2,828 patients with uncontrolled or resistant hypertension.
All three drugs lowered systolic pressure more than placebo, with baxdrostat and lorundrostat performing similarly. Benefits looked strongest in resistant hypertension. Risks rose too, including low blood pressure, high potassium, and low sodium. Because no trial pitted the drugs head to head, the authors present the ranking as a guide for doctors, not a final verdict.
Catalog record
| CREATOR | Ismaila Ajayi Yusuf, Olurotimi J. Badero, Alozie Ihesiulo, Micah Nnabuko Okwah, Abieyuwa Oshodin, Emmanuella Asikong, James Wright, James Wright, James Wright |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |